Results 1 to 10 of about 9,455 (122)

Risk factors for carfilzomib-related cardiovascular adverse events in Chinese patients with multiple myeloma: A real-world retrospective cohort study [PDF]

Journal of International Medical Research
Background Although an association between carfilzomib and cardiovascular adverse events has been well documented, the risk factors for carfilzomib-induced cardiovascular adverse events in the Chinese population remain unclear.
Xiao-Chen Wei, Fan Chen, Ying Xiao, Hai-Rong Lyu   +3 more
doaj   +2 more sources

Carfilzomib preserves dendritic cell phenotype and function compared with bortezomib [PDF]

Frontiers in Immunology
IntroductionDespite major therapeutic advances, multiple myeloma (MM) remains largely incurable. Moreover, side effects and toxicities of treatments compromise patients’ quality of life.
L. Wang, M. Dahlfrancis, M. Dahlfrancis, D. Dörfel, D. Dörfel, J. S. Walz, J. S. Walz, J. S. Walz, J. S. Walz, M. G. Klatt, M. G. Klatt, F. Grünebach, S. M. Rittig, S. M. Rittig, S. M. Rittig   +14 more
doaj   +2 more sources

Incidence and Associated Risk Factors in the Development of Carfilzomib-Induced Cardiovascular Toxicity [PDF]

Current Oncology
Background: Carfilzomib, a second-generation proteasome inhibitor, is widely used in multiple myeloma (MM) treatment but has been associated with cardiovascular adverse events (CVAEs). Real-world data evaluating the incidence and risk factors are limited.
Noor Lad, Jayda Esplund, Dennis Grauer, Shebli Atrash, Prerna Mewawalla, Tejaswi Gadela, Charles Porter, Muhammad Mushtaq, Jeries Kort, Donald C. Moore, Al-Ola Abdallah, Zahra Mahmoudjafari, Jordan Snyder   +12 more
doaj   +2 more sources

Empagliflozin Alleviates Carfilzomib-Induced Cardiotoxicity in Mice by Modulating Oxidative Stress, Inflammatory Response, Endoplasmic Reticulum Stress, and Autophagy

Antioxidants
Carfilzomib is an irreversible proteasome inhibitor used for multiple myeloma patients. However, carfilzomib treatment is associated with cardiovascular complications.
Mohamed S Dabour, Eman Rashad, Beshay N Zordoky   +2 more
exaly   +3 more sources

Higher Proteotoxic Stress Rather Than Mitochondrial Damage Is Involved in Higher Neurotoxicity of Bortezomib Compared to Carfilzomib

Redox Biology, 2020
Proteasome inhibitors have great success for their therapeutic potential against hematologic malignancies. First generation proteasome inhibitor bortezomib induced peripheral neuropathy is considered as a limiting factor in chemotherapy and its second ...
Buket Alpertunga, Maria A. Fedorova, Kazım Yalçın Arga   +2 more
exaly   +3 more sources

Carfilzomib-induced sinus bradycardia: A case report and literature review [PDF]

SAGE Open Medical Case Reports
Carfilzomib is a second-generation irreversible proteasome inhibitors commonly used in the treatment of relapsed or refractory multiple myeloma. However, cardiac toxicity (heart failure, hypertension, coronary heart disease, etc.) has become the main ...
Xincai Zhao, Demei Sun, Rong Xu, Yao Qiu, Sida Zhao, Cheng Guo, Chunkang Chang, Jianping Zhang   +7 more
doaj   +2 more sources

Carfilzomib for Relapsed and Refractory Multiple Myeloma

Cancer Management and Research, 2019
K Groen, NWCJ van de Donk, CAM Stege, S Zweegman, IS Nijhof Department of Hematology, VU University Medical Center, Amsterdam, Netherlands Abstract: Although the prognosis of multiple myeloma (MM) patients has dramatically improved during recent years ...
Groen K, van de Donk NWCJ, Stege CAM, Zweegman S, Nijhof IS   +4 more
exaly   +2 more sources

Pharmacovigilance study on neurological adverse reactions of proteasome inhibitors in the FDA adverse event reporting system [PDF]

Frontiers in Pharmacology
ObjectiveBortezomib, carfilzomib and ixazomib are the proteasome inhibitors (PIs) used to treat multiple myeloma (MM). We conducted a comprehensive pharmacovigilance analysis of their neurotoxicity using the Food and Drug Administration Adverse Event ...
Shuyue Li, Tao Ling, Yan Liu, Jun Li
doaj   +2 more sources

High-dose carfilzomib achieves superior anti-tumor activity over low-dose and recaptures response in relapsed/refractory multiple myeloma resistant to lowdose carfilzomib by co-inhibiting the β2 and β1 subunits of the proteasome complex

Haematologica, 2023
Optimal carfilzomib dosing is a matter of debate. We analyzed the inhibition profiles of proteolytic proteasome subunits β5, β2 and β1 after low-dose (20/27 mg/m2) versus high-dose (≥36 mg/m2) carfilzomib in 103 pairs of peripheral blood mononuclear ...
Xiang Zhou, Andrej Besse, Jessica Peter, Maximilian Johannes Steinhardt, Cornelia Vogt, Silvia Nerreter, Eva Teufel, Emilia Stanojkovska, Xianghui Xiao, Hannah Hornburger, Larissa Haertle, Max Mendez Lopez, Umair Munawar, Angela Riedel, Seungbin Han, Elmer Maurits, Herman S. Overkleeft, Bogdan Florea, Hermann Einsele, K. Martin Kortüm, Christoph Driessen, Lenka Besse, Leo Rasche   +22 more
doaj   +1 more source

Mineralocorticoid Receptor Pathway Is a Key Mediator of Carfilzomib-induced Nephrotoxicity: Preventive Role of Eplerenone

HemaSphere, 2022
Carfilzomib is an irreversible proteasome inhibitor indicated for relapsed/refractory multiple myeloma. Carfilzomib toxicity includes renal adverse effects (RAEs) of obscure pathobiology.
Panagiotis Efentakis, Sofia Lamprou, Manousos Makridakis, Ioanna Barla, Panagiota-Efstathia Nikolaou, Andriana Christodoulou, Costantinos Dimitriou, Nikolaos Kostomitsopoulos, Ioannis Ntanasis-Stathopoulos, Irene Theochari, Maria Gavriatopoulou, Harikleia Gakiopoulou, Androniki Tasouli, Antonia Vlahou, Evangelos Gikas, Nikolaos Thomaidis, Meletios-Athanasios Dimopoulos, Evangelos Terpos, Ioanna Andreadou   +18 more
doaj   +1 more source